Abstract:Glycosylation of the immunoglobulin G (IgG)-Fc tail is required for binding to Fc-gamma receptors (FcγRs) and complement-component C1q. A variety of IgG1-glycoforms is detected in human sera. Several groups have found global or antigen-specific skewing of IgG glycosylation, for example in autoimmune diseases, viral infections, and alloimmune reactions. The IgG glycoprofiles seem to correlate with disease outcome. Additionally, IgG-glycan composition contributes significantly to Ig-based therapies, as for example IVIg in autoimmune diseases and therapeutic antibodies for cancer treatment. The effect of the different glycan modifications, especially of fucosylation, has been studied before. However, the contribution of the 20 individual IgG glycoforms, in which the combined effect of all 4 modifications, to the IgG function has never been investigated. Here, we combined six glyco-engineering methods to generate all 20 major human IgG1-glycoforms and screened their functional capacity for FcγR and complement activity. Bisection had no effect on FcγR or C1q-binding, and sialylation had no- or little effect on FcγR binding. We confirmed that hypo-fucosylation of IgG1 increased binding to FcγRIIIa and FcγRIIIb by ~17-fold, but in addition we showed that this effect could be further increased to ~40-fold for FcγRIIIa upon simultaneous hypo-fucosylation and hyper-galactosylation, resulting in enhanced NK cell-mediated antibody-dependent cellular cytotoxicity. Moreover, elevated galactosylation and sialylation significantly increased (independent of fucosylation) C1q-binding, downstream complement deposition, and cytotoxicity. In conclusion, fucosylation and galactosylation are primary mediators of functional changes in IgG for FcγR- and complement-mediated effector functions, respectively, with galactose having an auxiliary role for FcγRIII-mediated functions. This knowledge could be used not only for glycan profiling of clinically important (antigen-specific) IgG but also to optimize therapeutic antibody applications.

Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

Complement activation by IgG subclasses is governed by their ability to oligomerize upon antigen binding

Factors affecting IgG4-mediated complement activation

DNA Nanostructure-Templated Antibody Complexes Provide Insights into the Geometric Requirements of Human Complement Cascade Activation

The structural requirements for complement activation by IgG: does it hinge on the hinge?

Activation of the alternative pathway of complement by human serum IgA

IgG hexamers initiate acute lung injury

Interaction Studies of Hexameric and Pentameric IgMs with Serum-Derived C1q and Recombinant C1q Mimetics

The Fc fragment of soluble IgMs binds C1q to activate the classical complement pathway, while inhibiting complement-dependent cytotoxicity

Regulation of humoral immunity by complement

Structural Insights into Immunoglobulin M

Cryo-EM analysis of complement C3 reveals a reversible major opening of the macroglobulin ring

How J-chain ensures the assembly of immunoglobulin IgM pentamers

Hexamerization: explaining the original sin of IgG-mediated complement activation in acute lung injury

Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets

The Ligands for Human IgG and Their Effector Functions

Complement: a key system for immune surveillance and homeostasis

Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities

Antibody density on bacteria regulates C1q recruitment by monoclonal IgG but not IgM

Structural basis for surface activation of the classical complement cascade by the short pentraxin C-reactive protein

Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen